Vedolizumab - CISMeF

Preferred Label : Vedolizumab;

NCIt synonyms : Immunoglobulin G1, Anti-(Human Integrin LPAM-1 (Lymphocyte Peyer's Patch Adhesion Molecule 1)) (Human-Mus musculus Heavy Chain), Disulfide with Human-Mus musculus kappa-chain, Dimer;

NCIt definition : A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7), with immunomodulating, anti-inflammatory, and potential antineoplastic activities. Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role in the homing of T-lymphocytes to intestinal tissue.;

UNII : 9RV78Q2002;

CAS number : 943609-66-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 943609-66-3 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Entyvio;

Molecule name : MLN0002; MLN02; LDP-02; LDP 02;

Details

Origin ID

C95798;

UMLS CUI

C2742797;

Automatic exact mappings (from CISMeF team)
- Vedolizumab [ICD-11 Extension code]
CISMeF manual mappings
- Vedolizumab (substance) [SNOMED CT concept]
Currated CISMeF NLP mapping
- Vedolizumab [LOINC component]
- vedolizumab [International Nonproprietary Name]
- vedolizumab [MeSH concept]
- vedolizumab [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing vedolizumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing vedolizumab (medicinal product) [SNOMED CT concept]
- Vedolizumab [LOINC component]
- Vedolizumab (substance) [SNOMED CT concept]
- vedolizumab [ATC Code]
- vedolizumab [International Nonproprietary Name]
- vedolizumab [MeSH concept]
- vedolizumab [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- vedolizumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Integrin Alpha4/Beta7 [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients